Home>>Signaling Pathways>> Others>>ABR-238901

ABR-238901 Sale

目录号 : GC63420

ABR-238901是S100A8/A9阻断剂,有效抑制了S100A8/A9与高级糖基化终产物受体(RAGE)以及Toll样受体4(TLR4)之间的相互作用。

ABR-238901 Chemical Structure

Cas No.:1638200-22-2

规格 价格 库存 购买数量
10mM (in 1mL DMSO)
¥2,464.00
现货
5mg
¥2,240.00
现货
10mg
¥4,200.00
现货
25mg
¥6,650.00
现货
50mg
¥10,640.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

Description

ABR-238901 is a newly developed blocker for S100A8/A9, which effectively inhibits the interaction between S100A8/A9 and the receptor for advanced glycation endproducts (RAGE) as well as toll-like receptor 4 (TLR4) [1-2].

ABR-238901(30 mg/kg;i.p) ameliorates septic cardiomyopathy in mice [3]. ABR-238901, administered at a dose of 10 mg/kg intraperitoneally, reduces neutrophil extracellular trap (NET) formation in abdominal sepsis by inhibiting S100A9[4]. In abdominal sepsis, ABR-238901 at doses of 30 mg/kg administered intraperitoneally reduced lung levels of MPO (a marker of neutrophil activation) by 74% [5]. In mice with multiple myeloma (MM), treatment with ABR-238901 at a dose of 30 mg/kg given orally daily for 5 days reduces angiogenesis in vivo[6]. Administering ABR-238901 at a dose of 30 mg/kg intraperitoneally for a short duration shifts the balance between inflammation and repair towards a reparatory environment in the ischemic myocardium [7].

References:

[1]. Zhu H, He M, et,al. Low-intensity pulsed ultrasound alleviates doxorubicin-induced cardiotoxicity via inhibition of S100a8/a9-mediated cardiac recruitment of neutrophils. Bioeng Transl Med. 2023 Jul 7;8(6):e10570. doi: 10.1002/btm2.10570. PMID: 38023700; PMCID: PMC10658545.

[2]. Mareş RG, Sabău AH, et,al. S100A8∕A9 is a valuable biomarker and treatment target to detect and modulate neutrophil involvement in myocardial infarction. Rom J Morphol Embryol. 2023 Apr-Jun;64(2):151-158. doi: 10.47162/RJME.64.2.04. PMID: 37518871; PMCID: PMC10520380.

[3]. Jakobsson G, Papareddy P, et,al. Therapeutic S100A8/A9 blockade inhibits myocardial and systemic inflammation and mitigates sepsis-induced myocardial dysfunction. Crit Care. 2023 Sep 29;27(1):374. doi: 10.1186/s13054-023-04652-x. PMID: 37773186; PMCID: PMC10540409.

[4]. Du F, Ding Z, et,al. S100A9 induces reactive oxygen species-dependent formation of neutrophil extracellular traps in abdominal sepsis. Exp Cell Res. 2022 Dec 15;421(2):113405. doi: 10.1016/j.yexcr.2022.113405. Epub 2022 Oct 31. PMID: 36328195.

[5]. Ding Z, Du F, et,al. Targeting S100A9 Reduces Neutrophil Recruitment, Inflammation and Lung Damage in Abdominal Sepsis. Int J Mol Sci. 2021 Nov 29;22(23):12923. doi: 10.3390/ijms222312923. PMID: 34884728; PMCID: PMC8658007.

[6]. De Veirman K, De Beule N, et,al. Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion. Cancer Immunol Res. 2017 Oct;5(10):839-846. doi: 10.1158/2326-6066.CIR-17-0192. Epub 2017 Sep 13. PMID: 28903971.

[7]. Marinković G, Koenis DS, et,al. S100A9 Links Inflammation and Repair in Myocardial Infarction. Circ Res. 2020 Aug 14;127(5):664-676. doi: 10.1161/CIRCRESAHA.120.315865. Epub 2020 May 21. PMID: 32434457.

ABR-238901是S100A8/A9阻断剂,有效抑制了S100A8/A9与高级糖基化终产物受体(RAGE)以及Toll样受体4(TLR4)之间的相互作用[1-2]

ABR-238901(30 mg/kg;i.p)改善了小鼠的感染性心肌病[3]。ABR-238901以每公斤10毫克的剂量腹腔注射,通过抑制S100A9减少了腹部感染的中性粒细胞外网(NET)的形成[4]。在腹部感染中,ABR-238901以30 mg/kg剂量腹腔注射,将肺部MPO(中性粒细胞活化标志物)水平降低了74%[5]。在多发性骨髓瘤(MM)小鼠中,每日口服30 mg/kg 的ABR-238901治疗5天可降低体内血管生成[6]。腹腔注射30 mg/kg的ABR-238901,短期内改变了缺血性心肌组织中炎症修复平衡,使其向修复环境转变[7]

实验参考方法

Animal experiment [1]:

Animal models

C57Bl/6NrJ mice (Female; 8-12 weeks age)

Preparation method

5 mg/kg LPS was used to induce endotoxemia through intraperitoneal injection. Subsequently, mice were administered ABR-238901 or PBS intraperitoneally at a dose of 30 mg/kg at 0 h and 6 h post-LPS injection, respectively.

Dosage form

30 mg/kg;i.p

Applications

ABR-238901 ameliorates septic cardiomyopathy.

References:

[1]. Jakobsson G, Papareddy P, et,al. Therapeutic S100A8/A9 blockade inhibits myocardial and systemic inflammation and mitigates sepsis-induced myocardial dysfunction. Crit Care. 2023 Sep 29;27(1):374. doi: 10.1186/s13054-023-04652-x. PMID: 37773186; PMCID: PMC10540409.

化学性质

Cas No. 1638200-22-2 SDF
分子式 C11H9BrClN3O4S 分子量 394.63
溶解度 DMSO : 33.33 mg/mL (84.46 mM; ultrasonic and warming and heat to 60°C) 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 2.534 mL 12.6701 mL 25.3402 mL
5 mM 0.5068 mL 2.534 mL 5.068 mL
10 mM 0.2534 mL 1.267 mL 2.534 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

产品文档

Quality Control & SDS

View current batch: